Effect of Montelukast Monotherapy on Oxidative Stress Parameters and DNA Damage in Children with Asthma

DILEK F., Ozkaya E. , Kocyigit A. , Yazici M. , KESGIN S., GEDIK A. H. , ...Daha Fazla

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, cilt.167, sa.2, ss.119-126, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 167 Konu: 2
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1159/000436967
  • Sayfa Sayıları: ss.119-126


Background: There is ample knowledge reported in the literature about the role of oxidative stress in asthma pathogenesis. It is also known that the interaction of reactive oxygen species with DNA may result in DNA strand breaks. The aim of this study was to investigate if montelukast monotherapy affects oxidative stress and DNA damage parameters in a population of pediatric asthma patients. Methods: Group I consisted of 31 newly diagnosed asthmatic patients not taking any medication, and group II consisted of 32 patients who had been treated with montelukast for at least 6 months. Forty healthy control subjects were also enrolled in the study. Plasma total oxidant status (TOS) and total anti-oxidant status (TAS) were measured to assess oxidative stress. DNA damage was assessed by means of alkaline comet assay. Results: The patients in both group I and group II had statistically significant higher plasma TOS (13.1 +/- 4 and 11.1 +/- 4.1 mu mol H2O2 equivalent/liter, respectively) and low TAS levels (1.4 +/- 0.5 and 1.5 +/- 0.5 mmol Trolox equivalent/liter, respectively) compared with the control group (TOS: 6.3 +/- 3.5 mu mol H2O2 equivalent/liter and TAS: 2.7 +/- 0.6 mmol Trolox equivalent/liter; p < 0.05). DNA damage was 18.2 +/- 1.0 arbitrary units (a.u.) in group I, 16.7 +/- 8.2 a.u. in group II and 13.7 +/- 3.4 a.u. in the control group. There were statistically significant differences only between group I and the control group ( p < 0.05). Conclusions: According to the findings, montelukast therapy makes only minimal but not statistically significant improvement in all TOS, TAS and DNA damage parameters. (C) 2015 S. Karger AG, Basel